Are the risks of esophageal cancer surgery high? How to treat it well?

Surgery is a traditional treatment for cancer. When doctors strongly recommend surgery, almost every family of a cancer patient has questions. I don’t know whether surgery is necessary, how effective it is, and how risky it is. The most common hazards caused by surgical treatment are "complications" or "sequelae". The former refers to symptoms caused by surgery, such as reflux esophagitis, anastomotic leakage, etc.; sequelae refer to symptoms that will still exist after a long period of recovery. Symptoms such as pain, muteness, etc. Of course, in addition to postoperative complications or sequelae, the worst situation is "death." For esophageal cancer patients, surgery has a high risk of death. Data from Japan shows that in esophageal cancer surgery in Japan, patients died after surgery. The rate can reach 2.2%, while it can reach 3.4% in the United States. There is currently no data on the mortality rate of esophageal cancer surgery in my country. However, the mortality rate of esophageal cancer surgery is related to the patient's age, physical strength, and scope of surgical resection. Therefore, patients and their families should carefully consider whether to undergo surgery, but they should not be blindly afraid of the risks of surgery and delay treatment. However, in recent years, due to the continuous progress of modern medicine, especially the application of specific anti-tumor immunotherapy in tumor diseases, cancer has achieved breakthroughs from the rapid development of cytology. It has been clinically proven that specific anti-tumor immunotherapy can overcome the shortcomings of the three traditional treatment methods of surgery, radiotherapy and chemotherapy, such as "incompleteness, easy metastasis, and large side effects", and can successfully solve the problem of tumor cure for more patients. Among this group of hospitals that apply specific anti-tumor immunotherapy, the Cancer Immunotherapy Center of Beijing Third Hospital is the most trusted by the majority of patients. "Specific anti-tumor immunotherapy" - the best treatment for patients with intermediate and advanced cancer. Specific anti-tumor immunotherapy is a brand-new biological tumor treatment jointly developed by our hospital, Stanford University School of Medicine and the American Association for Cancer Research. model. "Specific anti-tumor immunotherapy" overcomes the shortcomings of traditional surgery, radiotherapy and chemotherapy, and is more precise, accurate and thorough. This therapy achieves the purpose of scientific anti-cancer by cultivating the patient's own anti-cancer cells in vitro and then infusing them back into the patient's body. It relies on the action of biological agents to culture and inject it into the human body. It uses the most efficient specific immune cells DC, CIK, T, and NK cells in the human body to work together to mobilize the patient's body's defense mechanism to regulate the patient's body's biological function. It can kill cancer cells, activate immune cells, kill tiny cancer cells remaining in the body, and achieve the goal of treating tumors from the root. Warm reminder: "Specific anti-tumor immunotherapy" has been recognized as the fourth largest treatment after surgery, chemotherapy, and radiotherapy because of its advantages such as safety, effectiveness, no toxic side effects, and the ability to significantly improve patients' quality of life and survival. Cancer treatment method is the most active and promising treatment method among the comprehensive cancer treatment models in the 21st century. Since the adoption of this technology, more than 10,000 cancer patients have been successfully treated with its miraculous efficacy, and it has been recognized and trusted by the majority of patients, allowing the majority of cancer patients to once again see the hope of life. The above is the correct introduction, I hope it can be helpful to patients and their families.